Drug Transporter (DT) Information

General Information of DT
DT ID DTD0471
Gene Name SLC7A5
Protein Name L-type amino acid transporter 1
Gene ID
8140
UniProt ID
Q01650
TCDB ID
2.A.3.8.25
3D Structure

Crystal Structure

Crystallisation Method: EM

PDB ID: 6JMQ

Corresponding Chain: A

Sequence Length: 1-507

Detail: Struture Info

Synonyms 4F2 LC; 4F2 light chain; 4F2LC; CD98; CD98 light chain; CD98LC; D16S469E; E16; Integral membrane protein E16; LAT1; Large neutral amino acids transporter small subunit 1; MPE16; SLC7A5; Solute carrier family 7 member 5; hLAT1; y+ system cationic amino acid transporter
DT Family Amino Acid-Polyamine-Organocation (APC) Family
L-type Amino Acid Transporter (LAT) Family
Tissue Specificity Expressed abundantly in adult lung, liver,brain, skeletal muscle, placenta, bone marrow, testis, restinglymphocytes and monocytes, and in fetal liver. Weaker expressionin thymus, cornea, retina, peripheral leukocytes, spleen, kidney,colon and lymph node. During gestation, expression in the placentawas significantly stronger at full-term than at the mid-trimesterstage. Also expressed in all human tumor cell lines tested and inthe astrocytic process of primary astrocytic gliomas. Expressed inretinal endothelial cells and in the intestinal epithelial cellline Caco-2.
Function This sodium-independent, high-affinity transporter involved in cellular amino acid uptake and mediates the transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan. Involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Plays a role in neuronal cell proliferation (neurogenesis) in brain. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. May play an important role in high-grade gliomas. Mediates blood-to-retina L-leucine transport across the inner blood-retinal barrier which in turn may play a key role in maintaining large neutral amino acids as well as neurotransmitters in the neural retina. Acts as the major transporter of tyrosine in fibroblasts. When associated with LAPTM4B, recruits SLC3A2 and SLC7A5 to lysosomes to promote leucine uptake into these organelles and is required for mTORC1 activation.
Disease(s) Partial seizures [ICD-11: 8A68.0]
Short bowel syndrome [ICD-11: KB89.1]
Endogenous Substrate(s) S-nitroso-L-cysteine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            4 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Gabapentin
 Approved Drug Info Partial seizures 8A68.0 [1]
L-glutamine
 Approved Drug Info Short bowel syndrome KB89.1 [2]
Levodopa
 Approved Drug Info Parkinson's Disease 8A00.0 [3]
Pregabalin
 Approved Drug Info Neuropathic pain 8E43.0 [4]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
L-histidine
 Phase 2/3 Drug Info HARS Syndrome N.A. [5]
L-leucine
 Phase 2 Drug Info Major depressive disorder 6A70.3 [2]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Gabapentin Approved Drug Info hCMEC/D3 cells-LAT1 Km = 530 microM [1]
Levodopa Approved Drug Info Human embryonic kidney cells (HEK293)-LAT1 Km = 200 microM [3]
Pregabalin Approved Drug Info hCMEC/D3 cells-LAT1 Km = 288 microM [4]
References
1 Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013 Jun 1;85(11):1672-83.
2 Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34.
3 Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep. 2017 Mar 8;7:43580.
4 Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246.
5 The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health. Front Chem. 2018 Jun 22;6:243.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.